YU62499A - Nova so - Google Patents

Nova so

Info

Publication number
YU62499A
YU62499A YU62499A YU62499A YU62499A YU 62499 A YU62499 A YU 62499A YU 62499 A YU62499 A YU 62499A YU 62499 A YU62499 A YU 62499A YU 62499 A YU62499 A YU 62499A
Authority
YU
Yugoslavia
Prior art keywords
tartrate
salt
new salt
dicyclobutylamino
benzopyran
Prior art date
Application number
YU62499A
Other languages
English (en)
Inventor
Hakan Nyqvist
Daniel D. Sohn
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of YU62499A publication Critical patent/YU62499A/sh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/04Drugs for disorders of the urinary system for urolithiasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Nova so (R)-3-N,N-diciklobutil-amino-8-fluor-3,4-dihidro-2H-1-benzopiran-5-karboksamid vodonik tartrat, naročito njen (2R,3R)-tartrat, a posebno monohidrat (R)-3-N,N-diciklobutil-amino-8-fluor-3,4-dihidro-2H-1-benzopiran-5-karboksamid vodonik (2R, 3R)-tartrat, postupak za proizvodnju ove soli tartrata, primena soli u medicini, primena soli tartrata u proizvodnji farmaceutskih formulacija, i postupak za lečenje oboljenja centralnog nervnog sistema davanjem soli tartrata domaćinu kome je potrebno takvo lečenje.[A new salt (R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide hydrogen tartrate, particularly the (2R, 3R)-tartrate thereof, most particularly the (R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide hydrogen (2R,3R)-tartrate monohydrate, processes for the manufacture of said tartrate salt, the use of the salt in medicine, the use of the tartrate salt in the manufacture of pharmaceutical formulations, and a method for the treatment of CNS disorders by administration of the tartrate salt to a host in need of such treatment.
YU62499A 1997-05-30 1998-05-15 Nova so YU62499A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702066A SE510305C2 (sv) 1997-05-30 1997-05-30 Nytt salt

Publications (1)

Publication Number Publication Date
YU62499A true YU62499A (sh) 2002-06-19

Family

ID=20407187

Family Applications (1)

Application Number Title Priority Date Filing Date
YU62499A YU62499A (sh) 1997-05-30 1998-05-15 Nova so

Country Status (34)

Country Link
US (2) US6858645B2 (sh)
EP (1) EP0984952B1 (sh)
JP (1) JP3554338B2 (sh)
KR (1) KR20010013127A (sh)
CN (1) CN1198814C (sh)
AR (1) AR012751A1 (sh)
AT (1) ATE228121T1 (sh)
AU (1) AU729301B2 (sh)
BG (1) BG64051B1 (sh)
BR (1) BR9809519A (sh)
CA (1) CA2291732C (sh)
DE (1) DE69809547T2 (sh)
DK (1) DK0984952T3 (sh)
EE (1) EE03874B1 (sh)
ES (1) ES2187030T3 (sh)
HK (1) HK1025575A1 (sh)
HU (1) HUP0001878A3 (sh)
ID (1) ID23794A (sh)
IL (1) IL133234A (sh)
IS (1) IS1943B (sh)
MY (1) MY117960A (sh)
NO (1) NO995853L (sh)
NZ (1) NZ501075A (sh)
PL (1) PL337181A1 (sh)
PT (1) PT984952E (sh)
RU (1) RU2193560C2 (sh)
SE (1) SE510305C2 (sh)
SK (1) SK282755B6 (sh)
TR (1) TR199902926T2 (sh)
TW (1) TW510899B (sh)
UA (1) UA53720C2 (sh)
WO (1) WO1998054166A1 (sh)
YU (1) YU62499A (sh)
ZA (1) ZA984486B (sh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102888D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0102887D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0102886D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0301796D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use II
SE0301795D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use I
EP2022110B1 (en) * 2006-05-11 2011-10-12 Johnson Controls Saft Advanced Power Solutions LLC Modular battery system
JP5163931B2 (ja) * 2007-03-08 2013-03-13 株式会社リコー 定着装置及び画像形成装置
EP2065385A1 (en) * 2007-11-28 2009-06-03 Laboratorios SALVAT, S.A. Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester
CN103788043B (zh) * 2008-11-28 2016-02-03 中国医学科学院药物研究所 硝克柳胺化合物晶iv型、其制法和其药物组合物与用途
JP6393310B2 (ja) * 2013-04-26 2018-09-19 サノフイSanofi 5−クロロ−チオフェン−2−カルボン酸[(s)−2−[メチル−3−(2−オキソ−ピロリジン−1−イル)−ベンゼンスルホニルアミノ]−3−(4−メチル−ピペラジン−1−イル)−3−オキソ−プロプリル]アミドの酒石酸塩

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420151A (en) * 1989-12-22 1995-05-30 Aktiebolaget Astra Chroman derivatives
US5616610A (en) 1989-12-22 1997-04-01 Astra Aktiebolag (R)-5-carbamoyl-8-fluoro-3-N,N-disubstituted-amino-3,4-dihydro-2H-1-benzopyrans
IT1282705B1 (it) 1996-02-28 1998-03-31 Recordati Chem Pharm Uso di antagonisti del recettore serotoninergico 5-ht|a per il trattamento dell'incontinenza urinaria
US5990114A (en) 1996-02-28 1999-11-23 Recordati, S.A., Chemical And Pharmaceutical Company Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence

Also Published As

Publication number Publication date
HUP0001878A2 (hu) 2001-05-28
SE9702066L (sv) 1998-12-01
CN1198814C (zh) 2005-04-27
IS5270A (is) 1999-11-24
CA2291732C (en) 2003-12-30
NO995853D0 (no) 1999-11-29
SK282755B6 (sk) 2002-12-03
IL133234A (en) 2004-05-12
JP3554338B2 (ja) 2004-08-18
UA53720C2 (uk) 2003-02-17
DK0984952T3 (da) 2003-02-24
PL337181A1 (en) 2000-08-14
EE9900549A (et) 2000-06-15
CN1258290A (zh) 2000-06-28
KR20010013127A (ko) 2001-02-26
HK1025575A1 (en) 2000-11-17
BG64051B1 (bg) 2003-11-28
AU729301B2 (en) 2001-02-01
EP0984952B1 (en) 2002-11-20
EP0984952A1 (en) 2000-03-15
ATE228121T1 (de) 2002-12-15
SK159499A3 (en) 2000-10-09
AU7792398A (en) 1998-12-30
NZ501075A (en) 2001-08-31
RU2193560C2 (ru) 2002-11-27
CA2291732A1 (en) 1998-12-03
US20030109576A1 (en) 2003-06-12
EE03874B1 (et) 2002-10-15
DE69809547D1 (de) 2003-01-02
IS1943B (is) 2004-08-13
NO995853L (no) 2000-01-31
US20050085532A1 (en) 2005-04-21
ES2187030T3 (es) 2003-05-16
PT984952E (pt) 2003-03-31
TW510899B (en) 2002-11-21
TR199902926T2 (xx) 2000-03-21
ID23794A (id) 2000-05-11
DE69809547T2 (de) 2003-08-21
IL133234A0 (en) 2001-03-19
SE9702066D0 (sv) 1997-05-30
SE510305C2 (sv) 1999-05-10
MY117960A (en) 2004-08-30
BR9809519A (pt) 2000-06-20
WO1998054166A1 (en) 1998-12-03
BG103949A (en) 2000-07-31
AR012751A1 (es) 2000-11-08
ZA984486B (en) 1998-11-30
US6858645B2 (en) 2005-02-22
HUP0001878A3 (en) 2002-04-29
JP2002501527A (ja) 2002-01-15

Similar Documents

Publication Publication Date Title
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
CA2375908A1 (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
TW200510375A (en) New compounds
EP1933833B8 (en) Therapy for the treatment of overactive bladder
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
MXPA02005536A (es) Acidos aminopropilfosfinicos novedosos.
IS1904B (is) Hliðstæðar aðferðir við framleiðslu á nýjum (R)-5-karbamóýl-8-flúor-3-N,N-tvíútskiptum-amínó-3,4-díhýdró-2H-1-bensópýrönum
YU62499A (sh) Nova so
PL370529A1 (en) Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug
SE0102440D0 (sv) New compound
WO2004105690A3 (en) Treatment of chronic pain associated with drug or radiation therapy
DK1091733T3 (da) (-)-Pseudoephedrin som et sympatomimetisk lægemiddel
HK1079688A1 (en) Statin product for enhancing cognitive maintenance
HUP0300863A2 (hu) N-(3,5-diklór-2-metoxi-fenil)-4-metoxi-3-(1-piperazinil)-benzolszulfonamid, eljárás elżállítására és a vegyületet tartalmazó gyógyszerkészítmény
AU2002224847A1 (en) N-alkylated gaba compounds, processes for their preparation and their use as medicaments
MY133438A (en) Morpholinobenzamide salts
HUP0103544A2 (hu) (R)-3-(N,N-diciklobutil amino)-8-fluor-3,4dihidro-2H-1-benzopirán-5karboxamid-hidrogén-(2R,3R)tartarát monohidrátot és paroxelint tartalmazó gyógyszerkészítmény és eljárás az előállítására
AU6470400A (en) Nitroxy derivatives of (r) and (s)-carnitine
EP1632235A3 (en) Use of highly selective norepinephrine reuptake inhibitors for the treatment of mental disorders
UA88284C2 (ru) Твердая лекарственная форма, которая содержит действующее вещество из группы ингибиторов обратного захвата моноаминовых нейротрансмиттеров с 2,3-двухзамещенным тропановым скелетом, способ ее получения и применения
SE0102888D0 (sv) New formulation
PL367628A1 (en) Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia
CA2532330A1 (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
TH51655A (th) เกลือของ (r)-3-n,n-ไดไซโคลบิวทิลอะมิโน-8-ฟลูออโร-3,4-ไดไฮโดร-2h-1-เบนโซไพแรน-5-คาร์บอกซาไมด์ไฮโดรเจน (2r,r3)-ทาร์เทรต, สารผสมทางเภสัชกรรมที่มีเกลือดังกล่าวและกระบวนการสำหรับผลิตเกลือดังกล่าว
MX9704887A (es) Composiciones farmaceuticas para el tratamiento de trastornos depresivos.